Robert S. Mills

Robert S. Mills discloses dealings in 2 companies, chiefly Juniper Pharmaceuticals Inc and TFF Pharmaceuticals, Inc. Over a trading history stretching from 30 March 2006 to 3 July 2024, the count stands at 26 filings.

Both buying and selling appear: 2 purchases worth €32k, against 4 sales worth €1.4M. The net balance comes to €1.4M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 15 share grants and 4 option exercises.

The latest filing, published on 8 July 2024, reports a share grant in TFF Pharmaceuticals, Inc. The last insider purchase was made public on 15 August 2023, 1,166 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.